Nicholas Conrad Smith - Jul 3, 2025 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
CHIEF FINANCIAL OFFICER & CBO
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol
ANRO
Transactions as of
Jul 3, 2025
Transactions value $
$0
Form type
4
Date filed
7/8/2025, 05:20 PM
Previous filing
Feb 7, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith Nicholas Conrad CHIEF FINANCIAL OFFICER & CBO C/O ALTO NEUROSCIENCE, INC., 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW /s/ Erin R. McQuade, Attorney-in-Fact 2025-07-08 0002009130

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANRO Employee Stock Option (Right to Buy) Award +45K 45K Jul 3, 2025 Common Stock 45K $2.35 Direct F1, F2, F3
transaction ANRO Employee Stock Option (Right to Buy) Disposed to Issuer -45K -100% 0 Jul 3, 2025 Common Stock 45K $6.23 Direct F1, F2, F3
transaction ANRO Employee Stock Option (Right to Buy) Award +33.8K 33.8K Jul 3, 2025 Common Stock 33.8K $2.35 Direct F2, F3, F4
transaction ANRO Employee Stock Option (Right to Buy) Disposed to Issuer -33.8K -100% 0 Jul 3, 2025 Common Stock 33.8K $6.23 Direct F2, F3, F4
transaction ANRO Employee Stock Option (Right to Buy) Award +202K 202K Jul 3, 2025 Common Stock 202K $2.35 Direct F2, F3, F5
transaction ANRO Employee Stock Option (Right to Buy) Disposed to Issuer -202K -100% 0 Jul 3, 2025 Common Stock 202K $5.30 Direct F2, F3, F5
transaction ANRO Employee Stock Option (Right to Buy) Award +90K 90K Jul 3, 2025 Common Stock 90K $2.35 Direct F2, F3, F6
transaction ANRO Employee Stock Option (Right to Buy) Disposed to Issuer -90K -100% 0 Jul 3, 2025 Common Stock 90K $14.88 Direct F2, F3, F6
transaction ANRO Employee Stock Option (Right to Buy) Award +135K 135K Jul 3, 2025 Common Stock 135K $2.35 Direct F2, F3, F7
transaction ANRO Employee Stock Option (Right to Buy) Disposed to Issuer -135K -100% 0 Jul 3, 2025 Common Stock 135K $4.20 Direct F2, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date.
F2 The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.
F3 Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.
F4 25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F5 One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date.
F6 25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F7 25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.